Last ¥331.00 JPY
Change Today -8.00 / -2.36%
Volume 344.0K
4563 On Other Exchanges
As of 1:00 AM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

anges mg inc (4563) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/30/14 - ¥572.28
52 Week Low
10/16/14 - ¥232.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ANGES MG INC (4563)

Related News

No related news articles were found.

anges mg inc (4563) Related Businessweek News

No Related Businessweek News Found

anges mg inc (4563) Details

AnGes MG, Inc., a biopharmaceutical company, is engaged in the research and development, and practical application of genetic medicines. The company is primarily developing Hepatocy growth factor (HGF) genetic medicine, which improves blood circulation by regenerating blood vessels. Its products pipeline includes Collategene for the treatment of peripheral arterial diseases, ischemic heart diseases, Parkinson’s disease, and lymphedema; NFkB decoy oligonucleotide for the treatment of atopic dermatitis and disc degeneration; NFkB decoy oligonucleotide coated PTA balloon catheter for the prevention of vascular restenosis; and CUREPEPTIN functional peptides for the treatment of wounds. The company also provides Naglazyme for the treatment of mucopolysaccharidosis; and CIN therapeutic vaccine for cervical cancer. It has strategic alliances with Daiichi Sankyo Company, Limited for the development of HGF genetic medicine in the fields of peripheral arterial disease and Ischemic heart disease; with Vical, Inc. for the development of Allovectin; and with BioLeaders Corporation for the development of therapeutic vaccine for cervical intraepithelial neoplasia. The company was formerly known as MedGene Bioscience Co., Ltd. and changed its name to AnGes MG, Inc. in October 2001. AnGes MG, Inc. was founded in 1999 and is headquartered in Ibaraki, Japan.

38 Employees
Last Reported Date: 03/31/14
Founded in 1999

anges mg inc (4563) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

anges mg inc (4563) Key Developments

Vical Incorporated and AnGes MG Enter into Collaboration to Develop and Commercialize an Equine Polyclonal Antibody Therapy for Patients Afflicted with Ebola Virus Disease

Vical Incorporated and AnGes MG announced that they have entered into collaboration to develop and commercialize an equine polyclonal antibody therapy for patients afflicted with Ebola virus disease. No medicines or vaccines are currently approved for the treatment of Ebola. Unlike prophylactic vaccines, which require widespread vaccinations, multiple doses and time in order to mount a protective immune response prior to exposure, polyclonal antibody therapy offers a more targeted approach of providing immediate immune globulin as a treatment against Ebola virus. Therapeutic approaches utilizing equine polyclonal antibodies have been used for the treatment of viral diseases such as rabies, bacterial toxins such as tetanus and diphtheria, as well as black widow spider venom. The planned approach will be to isolate antibodies from the horses immunized with a DNA vaccine encoding an Ebola virus glycoprotein antigen. The antibodies will be purified and developed for the treatment of Ebola virus disease in humans. Under the agreement, Vical will develop and provide to AnGes a DNA vaccine encoding the glycoprotein antigen of the 2014 Zaire strain of Ebola virus, formulated with Vical's proprietary Vaxfectin® adjuvant. AnGes will receive the right to exclusively develop and commercialize the equine polyclonal antibody therapy in Japan and will be responsible for all development costs. Vical will receive an upfront payment and is eligible to receive royalties on net sales and a percentage of payments received by AnGes under any sub-licensing agreements.

AnGes MG, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

AnGes MG, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

AnGes MG, Inc. - Shareholder/Analyst Call

AnGes MG, Inc. - Shareholder/Analyst Call


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4563:JP ¥331.00 JPY -8.00

4563 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4563.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4563 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 29.3x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANGES MG INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at